* Ocean Biomedical Inc is expected to report resultson February 12 (estimated) for the period ending September 30 2023
*
* LSEG's mean analyst estimate for Ocean Biomedical Inc is for a loss of 15 cents per share.
* The one available analyst rating on the shares is "buy".
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Ocean Biomedical Inc is $17.45, above its last closing price of $0.55.
This summary was machine generated February 12 at 21:49 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments